EMA Withdrawn: Jcovden (previously COVID-19 Vaccine Janssen) (adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)) — Janssen-Cilag International NV

View source ↗

Summary

The EMA has withdrawn the European marketing authorization for Jcovden (COVID-19 vaccine Janssen), an Ad26.COV2-S vaccine, effective as of 26 July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Virus Infection

Drugs mentioned

• Jcovden (adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S))

Snippet

Status: Withdrawn. Therapeutic area: COVID-19 virus infection. MAH: Janssen-Cilag International NV. Decision date: 26/07/2024